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Abstract
BACKGROUND: Recurrent pregnancy loss is classically defined as the occurrence of three or more consecutive 
pregnancy loss. Recurrent pregnancy loss affects from 1-5% of the reproductive age couples. This diagnosis is both 
emotionally challenging and confusing for most couples, as the definitive diagnosis using conventional evaluations is 
found in fewer than half of the couples experiencing repeated loss.
AIM: The purpose of this study was to define the association between Factor V Leiden G1691A, Prothrombin 
G20210A, MTHFC677T mutations and recurrent pregnancy loss in a group of Sudanese women.
MATERIALS AND METHODS: This a retrospective analytical case control study was carried out at Omdurman 
Maternal Hospital, Sudan between July 2013 to July 2015. Consent was obtained from the ethical committee 
of the Faculty Research Board and Hospital of Omdurman Maternity Hospital (Sudan).  The study included a 
hundred pregnant females with a history of recurrent spontaneous abortion as the (case group) and ninety-five 
healthy reproductive Sudanese women as the (control group). The data was collected with the help of a structured 
questionnaire and direct interview to collect information. Identification of point mutation in factor V Leiden G1691A, 
prothrombin G20210A and MTHF C677T gene by polymerase chain reaction was performed. The odds ratio and the 
95% confidence interval (95%CI) were calculated for the presence of mutation case group and the control group and 
analyzed by SPSS program, version 17.0. 
RESULTS: The frequency of prothrombin G20210A, MTHFC677T, was low overall, except for the Factor V Leiden 
G1691A. The differences between patients and controls had no statistical significance (P- Value>0.05).
CONCLUSION: Our study confirms the low prevalence of inherited thrombophilias in Sudanese populations and 
it is unlikely that the tested thrombophilias play a role in the pathogenesis of recurrent pregnancy loss in  the 
Sudanse population.Therefore, we conclude that the low prevalence of Factor V Leiden, prothrombin G20210A and 
MTHFC677T in Sudanese women with RPL and  does not play a role in the pathogenesis of recurrent pregnancy 
loss among our population.
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Introduction
Pregnancy loss is defined as the loss of a 
pregnancy prior to 24 weeks gestation. Recurrent 
pregnancy loss has previously been defined as three 
or more pregnancy losses [1].The exact prevalence 
of RPL is difficult to estimate, but most studies 
report that RPL affects 1–2% of women [2]. There 
are numerous factors that may cause (RPL), but the 
underlying problem often remains undetected. Although 
much work has been done to identify the underlying 
mechanisms, the cause of miscarriage can be identified 
in only 50% of cases. The known causes of RPL include 
chromosomal and metabolic abnormalities, uterine 
anomalies, thrombophilia and immunologic factors [3].
Thrombophilia has been identified as one of the main 
causes of RPL with a percentage of  40%, early RPL. 
Although several studies on this topic are available in 
the literature to confirm this trend, rates of thrombophilia 
seem to differ from study to study because of different 
inclusion criteria and different ethnic backgrounds of the 
selected patients [4] The contribution of thrombophilias 
to adverse outcomes in pregnancy is controversial. 
Studies tend to be small, have population selection 
bias, and have differences in the diagnostic criteria. 
Inherited and acquired thrombophilias contribute 
further to an increased predisposition to thrombotic 
events. The overall impact of the inherited and acquired 
thrombophilias is low in the nonpregnant population, 
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and most patients never experience a thrombotic 
event [5]. Hereditary thrombophilia comprises several 
conditions, such as antithrombin (AT) III deficiency, 
protein S (PS) and protein C (PC) deficiencies, factor V 
Leiden, prothrombin 20210A mutation, elevated factor 
VIII level, and mutation of gene encoding the enzyme 
methylenetetrahydrofolate reductase (MTHFR) [6].
Factor V Leiden genetic disorder is characterized 
by poor response to activated protein C (APC). APC 
is a natural anticoagulant protein that cleaves and 
inactivates procoagulant factors Va and VIIIa, thereby 
decreasing the formation of thrombin [7]. Prothrombin, 
or factor II, is the precursor of thrombin. This protein is 
a vitamin K dependent zymogen that is produced by the 
liver and has a central role in the conversion of fibrinogen 
into fibrin [8].The mutation in prothrombin is associated 
with an increased plasma concentration of prothrombin, 
which leads to an increased potential for thrombin 
generation [9].The MTHFR gene is responsible for the 
production of the enzyme methylenetetrahydrofolate 
reductase (MTHFR). A mutation in the gene 
inhibits the production of this enzyme, result in 
hyperhomocystinemia and this  increase has been 
associated with poor pregnancy outcomes. Numerous 
studies have reported associations between Factor V 
Leiden G1691A, prothrombin G20210A, MTHFC677T 
Mutations polymorphisms with poor pregnancy 
outcomes [10,11,12]. This study aimed at testing the 
association between FVL, FII, MTHFR and RPL in 
Sudanese women. The frequencies of these mutations 
was statistically compared among cases with RPL 
and a control group of healthy women to test whether 
significant differences in mutation frequencies exist 
between the two groups.
Methods
The current study is a retrospective analytical 
case-control study designed to investigate the 
relationship between Factor V Leiden G1691A, 
methylenetetrahydrofolate reductase (MTHFR) C677T 
and  the prothrombin G20210A mutation variant 
and recurrent pregnancy loss. The study included a 
hundred Sudanese women who experienced three or 
more of the adverse pregnancy loss as case group in 
the Omdurman maternity hospital (Sudan)  and they 
were compared with ninety four healthy women who 
made up the control group with at least more than 
two normal pregnancies and without any history of 
adverse pregnancy outcome or recurrent miscarriages 
during the period from July 2013 to July 2015. We 
included each woman who at least three or more 
consecutive RPL outcomes with unknown caused 
had and excluded each women had known cause of 
RPL. After consents were obtained from the patients 
and control blood samples were collected from 
participants and total genomic DNA was isolated from 
blood leukocytes and the frequency of these gene 
mutations in the patients and controls  was determined 
using PCR-restriction fragment length polymorphism. 
DNA was extracted from the blood samples using 
Master pure DNA purification kit for blood GF-1 Blood 
DNA Extraction Kit, 50 PREPS (cat. No. GF-BD-050, 
Vivantis Technologies Sdn. Bhd., Malaysia). FV Leiden 
G1691A, MTHFR C677T and FII. a 345-bp genomic 
DNA fragment encompassing a part of the prothrombin 
gene that contains the mutation was amplified by PCR 
using specific primers Forward (5’TCT AGA AAC AGT 
TGC CTG GC-3’) and Reverse primer (5’ATA GCA 
CTG GGA GCA TTG AAG C-3). And 267-basepair 
(bp) segment of the factor V gene was amplified  using 
specific forward primer (5’TCA GGC AGG AAC AAC 
ACC AT-3’) and reverse primer 5’GGT TAC TTC AAG 
GAC AAA ATA CCT GTA AAG CT3. MTHFR gene 
by using the site specific primers Forward ( 5’ TGA 
AGG AGA AGG TGT CTG CGG GA-3’) and Reverse 
primers: 5’AGG ACG GTG CGG TGA GAG AGT G -3’. 
The reaction program was as follows: Denaturation at 
94°C for 30 seconds, annealing at 51°C for 30 seconds, 
extension at 72°C for 30 seconds,15 for 35 cycles 
and 72°C for 5 minutes. A master mix was prepared 
by adding Nuclease free water,10x buffer, dNT P, tow 
primers,Mgc l2,Taq DNA polymerase and DNA, the 
mixture was loaded into thermocycler according to the 
specific Temperature profile. The working solution of 1X 
TBE was prepared from the stock solution (1 L) which 
contained the following: 89 mM Tris base (108 gm), 89 
mM boric acid (55 gm) 40 ml of 0.5M EDTA, adjust pH to 
8.0.1.5% agarose was prepared from 1x TBE, and 5µl 
PCR products  were loaded by mixing PCR products 
with 1µl loading dye, run on the gel for 30 mins and 
visualized on UV  transilluminator. Factor V digested 
with 10 µl of DNA restriction enzyme MnI1 at 37°Cfor 
18 h, subjected to 2% low melting point agarose and 
Prothrombin product (10 μL) was digested with 20 U 
of Hind III, at 37°C for 16 h, and loaded into 2% low 
melting point agarose gel, eletropherosed at 90 volts 
for 60 mins. MTHFC677T was digested by enzyme 
(Hindfl) by Added 10 µl mixtures to the 10 µl MTHFR 
products, a quick spinning is needed, 5- Incubated at 
37 ºC 18 hours, and the reaction was stopped with 4 
µl prom phenol blue dye, then 18 µl digested products 
was loaded into 2% agarose. Data were statistically 
described in terms of mean ± standard deviation 
(± SD), median and range, or frequencies (number 
of cases) and percentages where appropriate[13,14]. 
The odds ratio (OR) and the 95% confidence interval 
(95%CI) were calculated for the presence of mutation 
between cases and controls and analyzed by SPSS 
program (version: 17.0). Data were analyzed using the 
Chi-square test to compare the prevalence of MTHFR 
mutation between patients and controls (The test was 
considered significant when  p-value <0.05). Ethical 
consent was obtained from the ethical committee at 
Omdurman Maternity Hospital (Sudan).
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Results
The participants included 194 women 
subjects. Out of them, 100 had a history of 3 or 
more events of recurrent fetal loss. Their mean 
age ± SD was 25 ± 4. Moreover, 94 women were 
healthy, and their mean age was 30 ± 4. (Table 1). 
Table 1: Distribution of study subjects according to age
Characteristics Patients n (%) Controls n (%)
Age group 17–24 10 (10.1) 13 (13.8)
25–29 29 (29.3) 28 (29.8)
30–34 27 (27.3) 36 (38.3)
35–39 21 (21.2) 8 (8.5)
≥40 12 (12.1) 9 (9.6)
Maternal age was divided into five major groups 
(17–24, 25–29, 30–34, 35–39, and ≥ 40). Abortion 
rates among these groups were represented 
by 38 (18.8), 26 (12.9%), 39 (19.2%), 40 
(19.8%), and 59 (29.2%), respectively (Figure 1). 
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Figure 1: Distribution of recurrent pregnancy loss cases according 
to age groups 
Factor V Leiden mutation distribution showed a higher 
prevalence among case group than the control group. 
Mutation was detected in 8 out of cases (8.0%) and in 
6 out of 94 of the control group (6.4%) p-value = 0.66, 
odds ratio = 1.28, 95% CI (0.42–3.84). The prevalence 
of heterozygous FVL mutation in RPL women was 
found to be 8%, but the control group was found to 
be 6.4%. Normal homozygous (G/G) among cases 
showed 92%, but the controls showed 93.6%. Alleles 
G allele occurred with a frequency of 96. % among 
cases and 96.8% in the controls, while mutant allele 
(A) was seen only in 4% of the cases. The frequency 
of a mutant allele (A) was 3.2 % and G allele occurred 
with a frequency of 96.8 % among controls. According 
to this result, there is statistically insignificant 
between the cases and controls group (Table 2). 
Table 2: Frequency of factor V (Leiden) mutation among cases 
of recurrent pregnancy loss compared to controls
Genotype Patients 
n (%)
Controls  
n (%)
p-value OR (95%CI)
Heterozygous G/A 8 (8.0) 6 (6.4) 0.66 1.28 (0.42 to 3.84)
Normal homozygous G/G 92 (92.0) 88 (93.6)
Alleles G 192 (96.0) 182 (96.8) 0.67 0.76 (0.27 to 2.33)
Alleles A 8 (4.0) 6 (3.2)
The prevalence of the prothrombin gene was 3% among 
cases with p-value = 0.091. However, no mutant gene 
was detected among the control group. According to 
the genotyping in cases, it showed (heterozygotes, 
3.0% and homozygotes, 97.0%), alleles G (98.5%) 
and alleles A (1.5%), while in the control group, it 
showed normal homozygous G/G (100%) and alleles 
G (alleles G). There was no significant association 
between cases carriage any of this mutation and 
risk with recurrent pregnancy miscarriage (Table 3). 
Table 3: Frequency of prothrombin mutation among cases of 
recurrent pregnancy loss compared to controls
Genotype Patients n (%) Controls n (%) p-value OR (95%CI)
Heterozygous G/A 3 (3.0) 0 0.091 0
Normal homozygous G/G 97 (97.0) 94 (100)
Alleles G 194 (98.5) 188 (100) 0.089 0
Alleles A 3 (1.5) 0
The frequency of heterozygous C/T MTHFR gene was 
3.0% in cases with p = 0.091; there was no mutant 
gene detected among the control group. The normal 
homozygous gene was 97.0% in cases, and 100% 
showed in the control group. The frequency of alleles C 
was 98.5% in cases and 100% in controls, while alleles 
T was 1.5%. There was no significant association 
between cases carriage any of this mutation and risk 
of recurrent mistcarriage (Table 4).
Table 4: Frequency of MTHFR mutation among cases of 
recurrent pregnancy loss compared to controls
Genotype Patients n (%) Controls n (%) p-value OR (95%CI)
Heterozygous C/T 3 (3.0) 0 0.091 0
Normal homozygous  C/C 97 (97.0) 94 (100)
Alleles T 3 (1.5) 0 0.089 0
Alleles C 194 (98.5) 188 (100)
Discussion
Exploring the relation between Factor V 
Leiden, Prothrombin and methylene gene mutation with 
recurrent pregnancy loss is a challenge. This is because 
recurrent pregnancy loss has multiple etiologies, where 
genetic factors are considered as one of those etiologies. 
Advance technology in molecular genetics provides an 
accurate and reliable tool to precisely study the genetic 
abnormalities associated with recurrent pregnancy loss 
and several studies have identified thrombophilia genes 
mutation as the principal cause of recurrent pregnancy 
loss. The present study is the first to report the 
frequency of inherited thrombophilia (Factor V Leiden 
G1691A, prothrombin G20210A and MTHFC677T) 
together among the same group of Sudanese patients 
with recurrent pregnancy loss. The results obtained in 
this study are in accordance with the results of previous 
research, and indicate that the MTHFR C677T, FVL, 
and FII G20210A polymorphisms are not associated 
with recurrent pregnancy loss, Fátima et al. [15], had 
investigated 100 women with three or more consecutive 
miscarriages and  concluded that neither FVL nor PT 
G20210A is associated with RM prior to 10 weeks of 
gestation. Other large prospective studies reported 
contradictory results stating that hypercoagulable 
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thrombophilic gene mutations are not increased in 
women with recurrent miscarriage [16], [17]. In another 
study conducted by Henry et.al, [18], they confirmed 
the low prevalence of inherited thrombophilias in non-
Caucasian populations and it is unlikely that the tested 
thrombophilias play a role in the pathogenesis of 
recurrent pregnancy loss in this Colombian population. 
They are also congruent with another study conducted 
by Abu-Asab et al., they did not find a significant 
association between FVL, FII, and MTHFR and RPL in 
the first and second trimester [19]. Our results are in 
contrast to another previous recurrent pregnancy loss 
studies that found a positive association between Factor 
V Leiden G1691A, prothrombin G20210A, MTHFC677T 
mutations and recurrent pregnancy loss. Tawfik et 
al.  had found MTHFR C667T, Factor V Leiden and 
prothrombin gene mutations are significantly increased 
in patients having recurrent miscarriages [20]. Another 
study conducted among Syrian women by W Al-Achkar 
et.al, indicate that RPL women with homozygous 
genotype for (C677T and A1298C) either alone or 
compound heterozygous genotypes have a high risk 
of pregnancy loss in Syrian women [21]. Another study 
conducted in northern area of Saudi Arabia among 
spontaneous miscarriage women by Fakhr-Eldeen et.al, 
concludes that FVL and PTH gene mutations, but not 
MTHFR were significantly prevalent and associated 
with RSM in the study population [22]. In Sudan some 
previous studies had investigated the frequency of 
these genes’ mutation but among people with other 
disorders not RPL, like deep venous thrombosis and 
the finding are varying [23], [24].The variation in findings 
could be explained by the differences in ethnicity, the 
study sample size and design as well as the other 
interacting genetic and environmental factors that 
affect the final thrombophilic phenotype of the RPL 
patients [25]. Exploring the relation between Factor V 
Leiden. Prothrombin and methylene gene mutation with 
recurrent pregnancy loss is a challenge. Several studies 
have identified thrombophilia as the principal cause 
of recurrent pregnancy loss [26]. However, reported 
studies often do not evaluate other causes of RPL in 
their inclusion and exclusion criteria. In addition, many 
authors suggest that methodological diversity, sample 
size and clinical heterogeneity may have a role in this 
discrepancy and contradiction.
Conclusion
We conclude that the low prevalence of factor 
V Leiden, prothrombin G20210A, and MTHFC677T 
in Sudanese women with RPL does not play a role in 
the pathogenesis of recurrent pregnancy loss among 
our population. Furthermore, larger-scale studies 
are required to clarify the association between these 
variants and RPL and their role in this condition.
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